Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang · 2026
Read Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer by Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13418743.txt.
Description
Ping Xu and colleagues identify a protein that helps colorectal cancer resist a standard chemotherapy drug. Oxaliplatin-based treatment remains the first choice for most patients, since immune therapy helps only a small share. The team focused on Tex10, a protein tied to a chromatin complex inside the cell nucleus.
In cell tests, removing Tex10 made tumors far more open to the drug, sparking a self-eating process that slowed cell growth. The same effect held in mouse tumor models and in organoids grown from patient tissue. Tex10 normally holds a non-standard form of the BAF complex together, and blocking that link broke the shield around the cancer cells. The findings mark Tex10 as a possible drug target for patients whose tumors no longer answer to standard care.
Catalog record
| CREATOR | Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |